1. Home
  2. SCPH vs JRVR Comparison

SCPH vs JRVR Comparison

Compare SCPH & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCPH
  • JRVR
  • Stock Information
  • Founded
  • SCPH 2013
  • JRVR 2002
  • Country
  • SCPH United States
  • JRVR Bermuda
  • Employees
  • SCPH N/A
  • JRVR N/A
  • Industry
  • SCPH Biotechnology: Pharmaceutical Preparations
  • JRVR Property-Casualty Insurers
  • Sector
  • SCPH Health Care
  • JRVR Finance
  • Exchange
  • SCPH Nasdaq
  • JRVR Nasdaq
  • Market Cap
  • SCPH 299.0M
  • JRVR 270.4M
  • IPO Year
  • SCPH 2017
  • JRVR 2005
  • Fundamental
  • Price
  • SCPH $5.62
  • JRVR $5.17
  • Analyst Decision
  • SCPH Buy
  • JRVR Buy
  • Analyst Count
  • SCPH 3
  • JRVR 4
  • Target Price
  • SCPH $12.00
  • JRVR $6.06
  • AVG Volume (30 Days)
  • SCPH 2.4M
  • JRVR 311.4K
  • Earning Date
  • SCPH 11-12-2025
  • JRVR 11-10-2025
  • Dividend Yield
  • SCPH N/A
  • JRVR 0.76%
  • EPS Growth
  • SCPH N/A
  • JRVR N/A
  • EPS
  • SCPH N/A
  • JRVR N/A
  • Revenue
  • SCPH $49,969,000.00
  • JRVR $665,342,000.00
  • Revenue This Year
  • SCPH $108.95
  • JRVR $2.19
  • Revenue Next Year
  • SCPH $78.30
  • JRVR $7.93
  • P/E Ratio
  • SCPH N/A
  • JRVR N/A
  • Revenue Growth
  • SCPH 107.79
  • JRVR N/A
  • 52 Week Low
  • SCPH $1.94
  • JRVR $3.00
  • 52 Week High
  • SCPH $6.28
  • JRVR $7.19
  • Technical
  • Relative Strength Index (RSI)
  • SCPH 52.96
  • JRVR 37.24
  • Support Level
  • SCPH N/A
  • JRVR $5.20
  • Resistance Level
  • SCPH $5.62
  • JRVR $5.43
  • Average True Range (ATR)
  • SCPH 0.04
  • JRVR 0.20
  • MACD
  • SCPH -0.21
  • JRVR -0.04
  • Stochastic Oscillator
  • SCPH 99.56
  • JRVR 11.64

About SCPH scPharmaceuticals Inc.

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.

About JRVR James River Group Holdings Ltd.

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.

Share on Social Networks: